𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

✍ Scribed by Cortes, Jorge E.; Kantarjian, Hagop; Shah, Neil P.; Bixby, Dale; Mauro, Michael J.; Flinn, Ian; O'Hare, Thomas; Hu, Simin; Narasimhan, Narayana I.; Rivera, Victor M.; Clackson, Tim; Turner, Christopher D.; Haluska, Frank G.; Druker, Brian J.; Deininger, Michael W.N.; Talpaz, Moshe

Book ID
118218196
Publisher
Massachusetts Medical Society
Year
2012
Tongue
English
Weight
608 KB
Volume
367
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dasatinib treatment for Philadelphia chr
Dasatinib treatment for Philadelphia chromosome-positive leukemias : Practical considerations
✍ Hanna Jean Khoury; François Guilhot; Timothy P. Hughes; Dong-Wook Kim; Jorge E. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

## Abstract Dasatinib is a highly potent Bcr‐Abl inhibitor that is approved for the treatment of imatinib‐resistant or ‐intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome‐positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with